Pregled bibliografske jedinice broj: 1001753
The GLI Code in Ovarian Cancer
The GLI Code in Ovarian Cancer // Translating Science of Medicine - Targets and Therapeutics - Fifth Meeting of the Croatian Association for Cancer Research with International Participation : Oral presentation, in Libri oncologici, Vol. 46 No. Supplement 1 / Ozretić, Petar ; Levanat, Sonja (ur.).
Zagreb: Klinički bolnički centar Sestre milosrdnice, 2018. str. 17-17 (pozvano predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1001753 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The GLI Code in Ovarian Cancer
Autori
Sabol, Maja
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Translating Science of Medicine - Targets and Therapeutics - Fifth Meeting of the Croatian Association for Cancer Research with International Participation : Oral presentation, in Libri oncologici, Vol. 46 No. Supplement 1
/ Ozretić, Petar ; Levanat, Sonja - Zagreb : Klinički bolnički centar Sestre milosrdnice, 2018, 17-17
Skup
5th Meeting of the Croatian Association for Cancer Research with International Participation: Translating Science to Medicine "Targets and Therapeutics" (HDIR-5)
Mjesto i datum
Zagreb, Hrvatska, 08.11.2018. - 10.11.2018
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Hedgehog-GLI signaling ; transcription factors ; GLI proteins ; GLI code ; ovarian cancer
Sažetak
Ovarian tumors are a heterogenic malignancy, often named “the silent killer” due to lack of symptoms, which leads to late detection of the disease. It is often diagnosed in the advanced stages when the tumor has already spread. Additional complication are the differenttissues of origin for different tumor types, or even of the same subtype. The Hedgehog signaling pathway has been implicated in ovarian tumors by several different mechanisms. Hyperactivation of the Hedgehog pathway can occur via hypermethylation of PTCH1 promoter, mutations in PTCH1 gene, microRNA activity, or through cross-talk with other signaling pathways. All these events eventually lead to activation of GLI proteins and to tilting the balance imparted by the GLI code towards activation of the pathway. Expression of GLI1 is usually associated with tumor progression in a clinical setting, but GLI2 and GLI3 also play a role by modifying the activity of GLI1 and transcription of their common transcriptional targets. In ovarian cancer, GLI3 protein is expressed in the full-length activator form, and not the shortened repressor form which is the predominant form for GLI3 protein. CRISPR/Cas9-generated knock-out ovarian cancer cell lines for each of the three GLI proteins show that all three GLI proteins are relevant for the pathway activation in ovarian cancer, including GLI3 which is usually considered a repressor.
Izvorni jezik
Hrvatski
Znanstvena područja
Biologija, Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
HRZZ-IP-2016-06-1268 - Novi molekularni mehanizmi kao mete ciljanih terapija: Interakcije molekula mikroRNA i signalnog puta Hedgehog-GLI u seroznom karcinomu jajnika (MIRnaGLI) (Levanat, Sonja, HRZZ - 2016-06) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb
Profili:
Maja Sabol
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus